A decade of RAD51C/D: Germline pathogenic variants and their phenotypic landscape

APC-related multiple salivary gland lesions: spatial transcriptomic analysis reveals progressive WNT activation

Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa

Data from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Data from Germline Missense Variants in <i>CDC20</i> Result in Aberrant Mitotic Progression and Familial Cancer

Data from Germline Missense Variants in <i>CDC20</i> Result in Aberrant Mitotic Progression and Familial Cancer

Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Data from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Data from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Data from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

FIGURE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S1 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S1 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S10 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S11 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S2 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S2 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S4 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Figure S4 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S5 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S7 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Figure S9 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer

Germline PDGFRB p.R987W pathogenic variant in two children with brain tumors

Multimodal analysis of rare BARD1 missense variant suggests its pathogenicity is conditional

PRSS2 stimulates tumor growth by remodeling the TME via repression of Tsp1

Supplementary Data from Germline Missense Variants in <i>CDC20</i> Result in Aberrant Mitotic Progression and Familial Cancer

Supplementary Figure 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 4 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 5 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 5 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 6 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 8 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 9 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure 9 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Figure Legends and Materials and Methods from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Supplementary Table 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Table 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Table 3 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer

Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 5 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 6 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Supplementary Table 7 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 1 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 2 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 3 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

TABLE 4 from Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation

Table S3 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Table S4 from SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer

Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

Tables S1, S2, S3 from Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition

“I just wanted more”: Hereditary cancer syndromes patients’ perspectives on the utility of circulating tumour DNA testing for cancer screening